Lawrence P. Kane - Publications

Affiliations: 
Immunology University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Immunology, Cell Biology

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Tilstra JS, Avery L, Menk AV, Gordon RA, Smita S, Kane LP, Chikina M, Delgoffe GM, Shlomchik MJ. Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. The Journal of Clinical Investigation. PMID 30130253 DOI: 10.1172/JCI120859  0.32
2018 Corredera E, Phong BL, Moore JA, Kane LP, Lee SE. TIM-3-Expressing Mast Cells Are Present in Chronic Rhinosinusitis with Nasal Polyps. Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 194599818774560. PMID 29759032 DOI: 10.1177/0194599818774560  0.36
2018 Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava RM, Kane LP, Lu B, Ferris RL. Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29712685 DOI: 10.1158/1078-0432.CCR-17-1350  0.32
2018 Avery L, Filderman J, Szymczak-Workman AL, Kane LP. Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion. Proceedings of the National Academy of Sciences of the United States of America. PMID 29463725 DOI: 10.1073/pnas.1712107115  0.32
2017 Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL. Increased PD-1+ and TIM-3+ TILs during cetuximab therapy inversely correlates with response in head and neck cancer patients. Cancer Immunology Research. PMID 28408386 DOI: 10.1158/2326-6066.CIR-16-0333  0.32
2017 Du W, Yang M, Turner A, Xu C, Ferris RL, Huang J, Kane LP, Lu B. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. International Journal of Molecular Sciences. 18. PMID 28300768 DOI: 10.3390/ijms18030645  0.32
2017 Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology. 6: e1261779. PMID 28197389 DOI: 10.1080/2162402X.2016.1261779  0.32
2016 Phong B, Kane LP. Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies. F1000research. 5: 251. PMID 30023044 DOI: 10.12688/f1000research.8132.2  0.36
2016 Phong B, Avery L, Menk AV, Delgoffe GM, Kane LP. Cutting Edge: Murine Mast Cells Rapidly Modulate Metabolic Pathways Essential for Distinct Effector Functions. Journal of Immunology (Baltimore, Md. : 1950). PMID 27974455 DOI: 10.4049/jimmunol.1601150  0.36
2016 Li J, Shayan G, Avery L, Jie HB, Gildener-Leapman N, Schmitt N, Lu BF, Kane LP, Ferris RL. Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk. Oncoimmunology. 5: e1200778. PMID 27853635 DOI: 10.1080/2162402X.2016.1200778  0.32
2015 Phong BL, Avery L, Sumpter TL, Gorman JV, Watkins SC, Colgan JD, Kane LP. Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation. The Journal of Experimental Medicine. PMID 26598760 DOI: 10.1084/jem.20150388  0.36
2015 Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane LP, Ferris RL. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Research. 75: 508-18. PMID 25480946 DOI: 10.1158/0008-5472.CAN-14-1215  0.32
2014 Ferris RL, Lu B, Kane LP. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. Journal of Immunology (Baltimore, Md. : 1950). 193: 1525-30. PMID 25086175 DOI: 10.4049/jimmunol.1400557  0.32
2014 Hamilton KS, Phong B, Corey C, Cheng J, Gorentla B, Zhong X, Shiva S, Kane LP. T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10. Science Signaling. 7: ra55. PMID 24917592 DOI: 10.1126/scisignal.2005169  0.36
2012 Lin J, Chen L, Kane LP. Murine Tim-1 is excluded from the immunological synapse. F1000research. 1: 10. PMID 24627760 DOI: 10.12688/f1000research.1-10.v2  0.76
2011 Lee J, Phong B, Egloff AM, Kane LP. TIM polymorphisms--genetics and function. Genes and Immunity. 12: 595-604. PMID 22048452 DOI: 10.1038/gene.2011.75  0.36
2011 Cheng J, Phong B, Wilson DC, Hirsch R, Kane LP. Akt fine-tunes NF-κB-dependent gene expression during T cell activation. The Journal of Biological Chemistry. 286: 36076-85. PMID 21862580 DOI: 10.1074/jbc.M111.259549  0.36
2011 Lee J, Su EW, Zhu C, Hainline S, Phuah J, Moroco JA, Smithgall TE, Kuchroo VK, Kane LP. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Molecular and Cellular Biology. 31: 3963-74. PMID 21807895 DOI: 10.1128/MCB.05297-11  0.4
2011 Su EW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology. 21: 1258-65. PMID 21187321 DOI: 10.1093/glycob/cwq214  0.4
2008 Su EW, Lin JY, Kane LP. TIM-1 and TIM-3 proteins in immune regulation. Cytokine. 44: 9-13. PMID 18706830 DOI: 10.1016/j.cyto.2008.06.013  0.4
2007 Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, Bruce JN, Kane LP, Kuchroo VK, Hafler DA. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science (New York, N.Y.). 318: 1141-3. PMID 18006747 DOI: 10.1126/science.1148536  0.4
2002 Kane LP, Lin J, Weiss A. It's all Rel-ative: NF-kappaB and CD28 costimulation of T-cell activation. Trends in Immunology. 23: 413-20. PMID 12133805  0.76
Show low-probability matches.